-
公开(公告)号:CO2024015816A2
公开(公告)日:2024-11-28
申请号:CO2024015816
申请日:2024-11-21
Applicant: VERTEX PHARMA
Inventor: HADIDA RUAH SARA SABINA , MCCARTNEY JASON , MILLER MARK THOMAS , ZHOU JINGLAN , PATEL URVI , CHUDYK EWA IWONA , HURLEY DENNIS JAMES , NEUBERT TIMOTHY DONALD , PINDER JOANNE LOUISE , DEMORET ROBERT MARTIN , VALIULIN ROMAN ASKATOVICH , KINTZER ALEXANDER FREDERIK , SLOCHOWER DAVID ROBERT , AERTGEERTS KATHLEEN , BECK ELIZABETH MARY , KNEGTEL RONALD MARCELLUS ALPHONSUS , NESAN SAVARIAR ELAMPRAKASH , WEBB PETER , GULEVICH ANTON V , ISHIHARA YOSHIHIRO , TRAN JOE A , SCHARF ADAM
IPC: A61P9/06 , A61K31/4375 , A61K31/47 , A61P25/02 , A61P29/00 , C07D215/233 , C07D401/04 , C07D471/04 , C07D519/00
Abstract: Se proporcionan compuestos, y sales farmacéuticamente aceptables de estos, útiles como inhibidores de canales de sodio. También se proporcionan composiciones farmacéuticas que comprenden los compuestos o sales farmacéuticamente aceptables y métodos de uso de los compuestos, sales farmacéuticamente aceptables y composiciones farmacéuticas en el tratamiento de diversos trastornos, incluido el dolor.
-
公开(公告)号:IL316422A
公开(公告)日:2024-12-01
申请号:IL31642224
申请日:2024-10-16
Applicant: VERTEX PHARMA , MILLER MARK THOMAS , HURLEY DENNIS JAMES , NEUBERT TIMOTHY DONALD , NESAN SAVARIAR ELAMPRAKASH , PATEL URVI , HADIDA RUAH SARA SABINA , MCCARTNEY JASON , ZHOU JINGLAN , DEMORET ROBERT MARTIN , VALIULIN ROMAN ASKATOVICH , KINTZER ALEXANDER FREDERIK , WEBB PETER , SLOCHOWER DAVID ROBERT , AERTGEERTS KATHLEEN , BECK ELIZABETH MARY , KNEGTEL RONALD MARCELLUS ALPHONSUS , CHUDYK EWA IWONA , PINDER JOANNE LOUISE , GULEVICH ANTON V , ISHIHARA YOSHIHIRO , TRAN JOE A , SCHARF ADAM
Inventor: MILLER MARK THOMAS , HURLEY DENNIS JAMES , NEUBERT TIMOTHY DONALD , NESAN SAVARIAR ELAMPRAKASH , PATEL URVI , HADIDA RUAH SARA SABINA , MCCARTNEY JASON , ZHOU JINGLAN , DEMORET ROBERT MARTIN , VALIULIN ROMAN ASKATOVICH , KINTZER ALEXANDER FREDERIK , WEBB PETER , SLOCHOWER DAVID ROBERT , AERTGEERTS KATHLEEN , BECK ELIZABETH MARY , KNEGTEL RONALD MARCELLUS ALPHONSUS , CHUDYK EWA IWONA , PINDER JOANNE LOUISE , GULEVICH ANTON V , ISHIHARA YOSHIHIRO , TRAN JOE A , SCHARF ADAM
Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
-
公开(公告)号:AU2021358063A9
公开(公告)日:2025-03-13
申请号:AU2021358063
申请日:2021-10-06
Applicant: VERTEX PHARMA
Inventor: MCCARTNEY JASON , ABELA ALEXANDER RUSSELL , ABRAHAM SUNNY , ANDERSON COREY DON , ARUMUGAM VIJAYALAKSMI , CHAU JACLYN , CLEMENS JEREMY , CLEVELAND THOMAS , COON TIMOTHY RICHARD , DWIGHT TIMOTHY A , FANNING LEV TYLER DEWEY , FRIEMAN BRYAN A , GROOTENHUIS PETER (DECEASED) , GULEVICH ANTON V , HADIDA RUAH SARA SABINA , ISHIHARA YOSHIHIRO , KHATUYA HARIPADA , KRENITSKY PAUL , MELILLO VITO , MILLER MARK THOMAS , PARASELLI PRASUNA , PIERRE FABRICE , SILINA ALINA , TRAN JOE A , UY JOHNNY , VALDEZ LINO , ZHOU JINGLAN
IPC: C07D515/04 , A61K31/519 , A61P43/00
Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
-
-